Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2026Acta Radiologica

Efficacy and safety of boosted transarterial radioembolization in patients with chemoembolization-refractory hepatocellular carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

GKGun Ha KimUlsan CollegeEKEunbyeol KoUlsan CollegeJKJeongyeon KimUlsan College

Discussion

Loading...

Member takes

Implication

Randomized trial assesses efficacy and safety of boosted TARE in TACE-refractory HCC, indicating potential for improved outcomes.

Key Points

  • To evaluate the efficacy and safety of boosted transarterial radioembolization in patients with chemoembolization-refractory hepatocellular carcinoma.
  • Retrospective analysis of 41 consecutive patients with TACE-refractory HCC receiving boosted TARE.
  • Evaluation of tumor response, time to local tumor progression, time to progression, overall survival, and adverse events.
  • Conducted between November 2021 and December 2025.
  • Objective response rate was 90.2%, with complete response in 31 patients (75.6%) and partial in 6 (14.6%).
  • Median overall survival was 31.8 months (95% CI=19.4–not reached).
  • Severe adverse events occurred in 4 (9.8%) patients, with 1 death due to sepsis after tumor rupture.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/6a58752d2b46c88ba9ad10a2https://doi.org/10.1177/02841851261468006
View Full Paper
Ask AI
Bookmark
Share